The invention provides a safe and economical nonprescription combination of acetaminophen, aspirin and caffeine (APAP/ASA/CAF) for use in treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities. In accordance with the present invention, the use of the APAP/ASA/CAF combination is also effective in aborting the prodrome phase of a migraine attack, prior to the onset of the migraine-associated symptoms, aborting the symptoms of migraine attack prior to the onset of severe, throbbing migraine pain, and aborting migraine pain after a migraine has fully developed. In accordance with the present invention, the efficacy of the APAP/ASA/CAF combination treatment in reducing and eliminating migraine pain is at a parity with the efficacy of sumatriptan, a known, but dissimilar, anti-migraine agent, used at similar dosing regimens. Use of the APAP/ASA/CAF combination composition treatment at the unit dose also advantageously reduces/obviates the need of the migraine sufferer to re-dose or re-medicate at the end of the dosing period in accordance with the present invention.
USE OF COMPOSITIONS CONTAINING THE COMBINATION OF ACETAMINOPHEN, ASPIRIN AND CAFFEINE TO ALLEVIATE THE PAIN AND SYMPTOMS OF MIGRAINE